Current Report Filing (8-k)
March 16 2017 - 7:38AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 16, 2017
Karyopharm Therapeutics Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-36167
|
|
26-3931704
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
85 Wells Avenue, 2nd Floor
Newton, MA
|
|
02459
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (617)
658-0600
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the
Form 8-K
filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b) under
the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c) under
the Exchange Act (17 CFR
240.13e-4(c))
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On March 16, 2017, Karyopharm
Therapeutics Inc. (the Company) issued a press release regarding its financial results for the quarter and fiscal year ended December 31, 2016 and will conduct a previously-announced, publicly available conference call to discuss
those results. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form
8-K
and is incorporated herein by reference.
The information provided under this Form
8-K
(including Exhibit 99.1) shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
99.1 Press release issued by Karyopharm Therapeutics Inc. on March 16, 2017.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
KARYOPHARM THERAPEUTICS INC.
|
|
|
|
|
Date: March 16, 2017
|
|
|
|
By:
|
|
/s/ Christopher B. Primiano
|
|
|
|
|
|
|
Christopher B. Primiano
|
|
|
|
|
|
|
Senior Vice President, Operations, Business Development, General Counsel and Secretary
|
EXHIBIT INDEX
|
|
|
Exhibit
Number
|
|
Description of Exhibit
|
|
|
99.1
|
|
Press release issued by Karyopharm Therapeutics Inc. on March 16, 2017.
|
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024